News
New Sementis CEO to Advance Vaccine Technology
September 2023 Biotechnology company Sementis will advance its position at the forefront of vaccine technology with the...
November 2018
Australian biotechnology firm Sementis has entered into a research and development (R&D) partnership with UK-based Enesi Pharma for the development of potential vaccine candidates to treat peanut allergy and chikungunya/Zika infection.
Read more in Pharmaceutical Technology here.
News
September 2023 Biotechnology company Sementis will advance its position at the forefront of vaccine technology with the...
News
January 2023 Sementis has exciting news. We’re pleased to announce that we’ve been awarded a $3 million Federal...
News
December 2022 Sementis are grateful and proud to have the support of DMTC Ltd to advance research and development...